Related references
Note: Only part of the references are listed.Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
Alejandra Bernardini et al.
CANCERS (2022)
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T. Powles et al.
ANNALS OF ONCOLOGY (2022)
Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need
Kamaneh Montazeri et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.
Peter H. O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin
Susanne Deininger et al.
CANCERS (2021)
Metastatic Urothelial Cancer: a rapidly changing treatment landscape
Carlos Stecca et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)
Melissa Bersanelli et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2021)
The global burden of urinary bladder cancer: an update
Anke Richters et al.
WORLD JOURNAL OF UROLOGY (2020)
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study
Reut Hadash-Bengad et al.
FRONTIERS IN ONCOLOGY (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series
Aristotelis Bamias et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Khalil Saleh et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
Francesco Soria et al.
WORLD JOURNAL OF UROLOGY (2018)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
Gustavo Schvartsman et al.
LUNG CANCER (2017)
Excellent response to chemotherapy post immunotherapy
Ashish D. Dwary et al.
ONCOTARGET (2017)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)